Food Peptides That Lower Blood Pressure

Blood Pressure Peptides

-5.1 mmHg systolic

A meta-analysis of clinical trials found food-protein-derived peptides reduced systolic blood pressure by an average of 5.1 mmHg, with greater effects in hypertensive participants.

Pripp et al., Food & Nutrition Research, 2008

Pripp et al., Food & Nutrition Research, 2008

View as image

Every time your body digests protein, enzymes break polypeptide chains into shorter fragments. Some of these fragments happen to fit into the active site of angiotensin-converting enzyme (ACE), the same enzyme that pharmaceutical ACE inhibitors target to lower blood pressure. This is not a coincidence of drug design; it was the observation that peptides from snake venom inhibited ACE that led to the development of captopril, the first ACE inhibitor drug, in the 1970s. The same principle applies to peptides released during digestion of milk, fish, eggs, and plant proteins. These food-derived ACE inhibitory peptides have been tested in dozens of clinical trials, with meta-analyses showing modest but consistent blood pressure reductions. The connection to the broader renin-angiotensin system and to pharmaceutical approaches like sacubitril/valsartan places food peptides in a continuum from dietary intervention to drug therapy.

How Food Peptides Inhibit ACE

The renin-angiotensin system (RAS) is the body's primary blood pressure regulation pathway. Renin cleaves angiotensinogen to produce angiotensin I, which ACE then converts to angiotensin II, a potent vasoconstrictor. ACE also degrades bradykinin, a vasodilator. Blocking ACE therefore both reduces vasoconstriction and preserves vasodilation.

Food-derived peptides inhibit ACE through competitive binding. The enzyme's active site contains a zinc atom coordinated by specific amino acid residues. Short peptides (2-12 amino acids) with hydrophobic residues at the C-terminus and branched-chain or aromatic amino acids at specific positions can occupy this active site and prevent angiotensin I from being processed.^[1]

The structural requirements for ACE inhibition have been mapped in detail. Peptides with proline, tryptophan, phenylalanine, or tyrosine at the C-terminal position tend to have the strongest ACE inhibitory activity. Dipeptides and tripeptides are often more potent than longer sequences because they can be absorbed intact from the gut. The IC50 (concentration required for 50% ACE inhibition) of food-derived peptides ranges from micromolar to millimolar, compared to nanomolar for pharmaceutical ACE inhibitors. This potency gap explains why food peptides produce smaller blood pressure reductions.

Beyond direct ACE inhibition, some food peptides also inhibit renin (blocking the first step in the cascade), activate endothelial nitric oxide synthase (promoting vasodilation), reduce oxidative stress in blood vessels, and exert anti-inflammatory effects on the vascular endothelium. These multiple mechanisms may explain why clinical blood pressure effects sometimes exceed what in vitro ACE inhibition potency alone would predict.

Dairy-Derived Peptides

The Lactotripeptides: VPP and IPP

The most extensively studied food-derived antihypertensive peptides are Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP), released from beta-casein and kappa-casein during fermentation of milk by Lactobacillus helveticus. These tripeptides were first identified in the Japanese fermented milk drink Calpis (marketed as Ameal in some regions) in the 1990s.

Clinical evidence: Multiple randomized controlled trials in Japan and Europe have tested VPP/IPP supplementation. The Japanese trials consistently showed systolic blood pressure reductions of 5-10 mmHg in mildly hypertensive subjects. European trials produced smaller but still significant effects. A Cochrane-style analysis of all available trials estimated an average systolic reduction of 3-4 mmHg with VPP/IPP supplementation.

The geographic discrepancy in effect size has been debated. Possible explanations include differences in baseline blood pressure (higher in Japanese study populations), genetic variation in ACE polymorphisms, dietary context, and study design differences. The Japan-Europe effect size gap does not invalidate the finding but complicates dosing recommendations.

Casein Hydrolysate Peptides

Enzymatic hydrolysis of casein produces a range of ACE inhibitory peptides beyond VPP and IPP. Mizuno et al. (2005) conducted a placebo-controlled study of casein hydrolysate in subjects with high-normal blood pressure and mild hypertension, demonstrating significant blood pressure reduction.^[2]

A 2025 randomized, double-blind, placebo-controlled trial found that ACE inhibitory casein peptides reduced both systolic and diastolic blood pressure by approximately 9.4% and 9.5% respectively. The study also detected beneficial shifts in gut microbiota composition, suggesting that the blood pressure effect may involve gut-mediated pathways in addition to direct ACE inhibition.

Whey-Derived Peptides

Whey protein hydrolysis generates peptides including alpha-lactalbumin fragments and beta-lactoglobulin fragments with ACE inhibitory activity. Clinical data on whey-derived peptides specifically is less extensive than for casein, but whey protein hydrolysates have shown blood pressure-lowering effects in some trials. The combination of dairy sources (casein + whey) in whole milk fermentation likely produces a broader spectrum of bioactive peptides than either protein alone.

Fish-Derived Peptides

Fish proteins are rich in ACE inhibitory peptides, with the strongest evidence coming from sardine, bonito, and salmon sources.

Bonito peptides. The bonito fish peptide supplement Vasotensin (containing the peptide LKPNM and its derivative LKP) reduced blood pressure in borderline and mild hypertensive subjects in Japanese clinical trials. These peptides are absorbed intact from the gut and demonstrate ACE inhibitory activity at physiologically achievable concentrations.

Sardine peptides. The sardine muscle peptide Valtyron (containing VY, Val-Tyr) is marketed as a blood pressure-supporting supplement. Clinical trials in Japan showed modest but consistent systolic blood pressure reductions.

Salmon peptides. Salmon skin collagen hydrolysates contain ACE inhibitory sequences released during enzymatic digestion. The thermolysin hydrolysis of salmon skin produces peptides that reduce blood pressure in spontaneously hypertensive rats, though human clinical data is limited.

Marine peptides offer potential advantages: fish proteins contain high proportions of the hydrophobic and aromatic amino acids that confer ACE inhibitory activity, and the peptides are often small enough (2-5 amino acids) to survive gastrointestinal digestion and be absorbed intact.

Plant-Derived Peptides

Soy Peptides

Soy protein hydrolysates contain multiple ACE inhibitory sequences, and soy consumption has long been associated with lower blood pressure in epidemiological studies. The specific peptides responsible include sequences from glycinin and beta-conglycinin. Soy peptides have shown blood pressure-lowering effects in some clinical trials, though results are less consistent than for dairy peptides. Soy isoflavones may contribute independently to the blood pressure effect, complicating attribution to peptides specifically.

Other Plant Sources

Research has identified ACE inhibitory peptides from hemp (achieving 70% ACE inhibition and 35% renin inhibition in vitro), pigeon pea, lentil, chickpea, flaxseed, rapeseed, and rice bran hydrolysates. Most plant-derived peptide research is at the in vitro or animal model stage. Clinical trial data for specific plant-derived antihypertensive peptides is sparse compared to dairy and fish sources.^[3]

The plant peptide space has growing commercial interest as demand for non-animal-derived functional foods increases. Pea protein, hemp protein, and rice protein hydrolysates are being developed as supplements, though clinical validation lags behind dairy peptide products.

Bioavailability: The Critical Variable

An ACE inhibitory peptide identified in vitro is not automatically effective in vivo. The peptide must survive gastric acid, resist pancreatic protease digestion, be absorbed across the intestinal epithelium, and reach the target tissue (vascular endothelium, kidney) at a sufficient concentration to inhibit ACE.

Shorter peptides (2-3 amino acids) have a bioavailability advantage: they can be transported intact by peptide transporters (PepT1) in the small intestine. Longer peptides are more likely to be degraded during digestion. However, some longer sequences that are inactive themselves may be converted to active shorter peptides during digestion, a phenomenon called "prodrug" behavior.

The tripeptides VPP and IPP are absorbed intact in humans, as demonstrated by their detection in plasma after oral administration. This confirmed that the in vitro ACE inhibitory activity translates to systemic bioavailability. For many other food-derived peptides, bioavailability data is incomplete.

What the Evidence Supports

Consistent finding: Food-protein-derived peptides, particularly dairy lactotripeptides (VPP/IPP) and casein hydrolysates, reduce blood pressure by approximately 3-5 mmHg systolic and 1.5-2.5 mmHg diastolic in clinical trials. The effect is larger in hypertensive than normotensive individuals.

Clinical significance: A 5 mmHg systolic reduction at the population level reduces stroke risk by approximately 14% and coronary heart disease risk by approximately 9% (Lewington et al., Lancet, 2002). Food peptides producing this level of reduction in hypertensive individuals are clinically relevant, particularly for prehypertension management.

Limitations: Food peptide effects are modest compared to pharmaceutical ACE inhibitors (enalapril reduces systolic BP by 8-10 mmHg). The effect varies by population, baseline blood pressure, and peptide source. Long-term adherence data is limited. Regulatory status varies by country: some food peptide products are approved as "Foods for Specified Health Uses" (FOSHU) in Japan but lack equivalent regulatory recognition elsewhere.

Not established: Whether food-derived peptides reduce hard cardiovascular outcomes (heart attack, stroke, cardiovascular death). No long-term outcomes trials have been conducted. The blood pressure reduction data supports biological plausibility but does not constitute proof of cardiovascular protection.^[4]

The Bottom Line

Food-derived peptides from dairy, fish, and plant proteins inhibit ACE and reduce blood pressure by 3-5 mmHg systolic in clinical trials. The dairy tripeptides VPP and IPP have the strongest evidence base, with multiple RCTs and commercial products available. Fish-derived peptides from bonito and sardine sources have clinical support in Japanese studies. Plant-derived ACE inhibitory peptides are well characterized in vitro but lack comparable clinical trial data. The blood pressure reduction is modest compared to pharmaceutical ACE inhibitors but may be clinically relevant for prehypertension. No long-term cardiovascular outcomes data exists for food peptide interventions.

Frequently Asked Questions

Can food peptides lower blood pressure?

Clinical trial meta-analyses show food-protein-derived peptides reduce systolic blood pressure by 3-5 mmHg and diastolic by 1.5-2.5 mmHg on average. The effect is strongest in people with elevated blood pressure (above 140/85 mmHg) and has been demonstrated most consistently with dairy-derived lactotripeptides (VPP and IPP from fermented milk) and casein hydrolysates. The reduction is modest compared to medications but may be clinically meaningful for borderline hypertension.

What foods contain ACE inhibitory peptides?

ACE inhibitory peptides are released during digestion of many protein-rich foods. The strongest clinical evidence exists for fermented dairy products (particularly those fermented with Lactobacillus helveticus), casein protein hydrolysates, and fish proteins from bonito, sardine, and salmon. Plant sources including soy, hemp, lentil, and pea protein also contain ACE inhibitory sequences, though clinical data is less extensive.

What are VPP and IPP peptides?

VPP (Val-Pro-Pro) and IPP (Ile-Pro-Pro) are tripeptides released from milk casein during fermentation by Lactobacillus helveticus bacteria. They are the most extensively studied food-derived ACE inhibitory peptides, with clinical trials in Japan and Europe showing blood pressure reductions of 3-10 mmHg systolic. They are found in the Japanese fermented milk drink Calpis/Ameal and have been absorbed intact through the human intestine at blood pressure-lowering concentrations.

Are food peptides as effective as blood pressure medication?

Food-derived ACE inhibitory peptides reduce systolic blood pressure by approximately 3-5 mmHg, compared to 8-10 mmHg for pharmaceutical ACE inhibitors like enalapril or lisinopril. Food peptides are substantially less potent because their IC50 values for ACE inhibition are in the micromolar range versus nanomolar for drugs. Food peptides may be appropriate for prehypertension or as adjuncts to medication, but they are not substitutes for pharmaceutical treatment of established hypertension.

Do food-derived blood pressure peptides have side effects?

No significant adverse effects have been reported in clinical trials of food-derived antihypertensive peptides. Unlike pharmaceutical ACE inhibitors, food peptides do not cause the dry cough associated with bradykinin accumulation, likely because their ACE inhibition is weaker and more transient. The main limitation is not safety but efficacy: the blood pressure reduction is modest and may not be sufficient for people with moderate-to-severe hypertension who require pharmaceutical treatment.

Can fermented milk lower blood pressure?

Fermented milk products containing the lactotripeptides VPP and IPP have reduced blood pressure in multiple randomized controlled trials. The effect is most consistent in Japanese studies (5-10 mmHg systolic reduction) and smaller but still present in European trials (2-4 mmHg). Commercial products like Calpis/Ameal and Evolus are specifically marketed for blood pressure support based on this clinical evidence. Regular consumption over several weeks is required to see effects.